Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Bressel

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
Journal of Surgical Oncology|January 14, 2021
The role of <sup>18</sup> F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective studySuren Subramaniam, Jason Callahan, Mathias Bressel, et al.
Technology in Cancer Research & Treatment|January 11, 2015
Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy PlanningShankar Siva, Thomas Devereux, David L Ball, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 22, 2018
What <sup>18</sup>F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?Guy-Anne Turgeon, Amir Iravani, Tim Akhurst, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 11, 2025
A prospective study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancerNeil D Wallace, Mathias Bressel, Nick Hardcastle, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2022
Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for OligometastasesShankar Siva, Gavin Jones, Mathias Bressel, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II TrialConstanza Vargas, Joe Carrello, Mathias Bressel, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
Journal of Surgical Oncology|January 14, 2021
The role of <sup>18</sup> F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective studySuren Subramaniam, Jason Callahan, Mathias Bressel, et al.
Technology in Cancer Research & Treatment|January 11, 2015
Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy PlanningShankar Siva, Thomas Devereux, David L Ball, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 22, 2018
What <sup>18</sup>F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?Guy-Anne Turgeon, Amir Iravani, Tim Akhurst, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 11, 2025
A prospective study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancerNeil D Wallace, Mathias Bressel, Nick Hardcastle, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2022
Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for OligometastasesShankar Siva, Gavin Jones, Mathias Bressel, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II TrialConstanza Vargas, Joe Carrello, Mathias Bressel, et al.
Pageof 14